
Experience
LB Pharmaceuticals Announces $285 Million Upsized IPO
September 12, 2025
Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).
Related contacts
Related Practices & Industries
MannKind to Acquire scPharmaceuticals for up to $360 Million
August 25, 2025
Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million
Related contacts
Related Practices & Industries
Heartflow Announces $364.2 Million Upsized IPO
August 11, 2025
Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.
Related contacts
Related Practices & Industries
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
August 6, 2025
Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on an up to $500 million strategic financing agreement with funds managed by Blackstone.
Related contacts
Related Practices & Industries
Contentsquare Enters Definitive Agreement to Acquire Loris AI
July 30, 2025
Cooley advised Contentsquare, an all-in-one experience intelligence platform, on its definitive agreement to acquire Loris AI, a conversation intelligence platform, to give business leaders a deeper, more accurate view of the full customer journey – from click to conversation.
Related contacts
Related Practices & Industries
Related news and events
Admissions and credentials
Missouri
New York
Colorado